Literature DB >> 30355236

G-Protein-Coupled Receptors in Heart Disease.

Jialu Wang1, Clarice Gareri1, Howard A Rockman1,2,3.   

Abstract

GPCRs (G-protein [guanine nucleotide-binding protein]-coupled receptors) play a central physiological role in the regulation of cardiac function in both health and disease and thus represent one of the largest class of surface receptors targeted by drugs. Several antagonists of GPCRs, such as βARs (β-adrenergic receptors) and Ang II (angiotensin II) receptors, are now considered standard of therapy for a wide range of cardiovascular disease, such as hypertension, coronary artery disease, and heart failure. Although the mechanism of action for GPCRs was thought to be largely worked out in the 80s and 90s, recent discoveries have brought to the fore new and previously unappreciated mechanisms for GPCR activation and subsequent downstream signaling. In this review, we focus on GPCRs most relevant to the cardiovascular system and discuss traditional components of GPCR signaling and highlight evolving concepts in the field, such as ligand bias, β-arrestin-mediated signaling, and conformational heterogeneity.

Entities:  

Keywords:  GPCR; arrestin; bias; coronary artery disease; heart failure; hypertension

Mesh:

Substances:

Year:  2018        PMID: 30355236      PMCID: PMC6205195          DOI: 10.1161/CIRCRESAHA.118.311403

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  253 in total

Review 1.  Adenosine as an antiarrhythmic agent.

Authors:  S L Wilbur; F E Marchlinski
Journal:  Am J Cardiol       Date:  1997-06-19       Impact factor: 2.778

2.  Genetic evidence that β-arrestins are dispensable for the initiation of β2-adrenergic receptor signaling to ERK.

Authors:  Morgan O'Hayre; Kelsie Eichel; Silvia Avino; Xuefeng Zhao; Dana J Steffen; Xiaodong Feng; Kouki Kawakami; Junken Aoki; Karen Messer; Roger Sunahara; Asuka Inoue; Mark von Zastrow; J Silvio Gutkind
Journal:  Sci Signal       Date:  2017-06-20       Impact factor: 8.192

3.  Chronic administration of oral vasopressin type 2 receptor antagonist tolvaptan exerts both myocardial and renal protective effects in rats with hypertensive heart failure.

Authors:  Hanako Morooka; Yoshitaka Iwanaga; Yodo Tamaki; Toru Takase; Yasumitsu Akahoshi; Yoshimasa Nakano; Hiroyuki Fujiki; Shunichi Miyazaki
Journal:  Circ Heart Fail       Date:  2012-05-24       Impact factor: 8.790

4.  Long-Term Biased β-Arrestin Signaling Improves Cardiac Structure and Function in Dilated Cardiomyopathy.

Authors:  David M Ryba; Jieli Li; Conrad L Cowan; Brenda Russell; Beata M Wolska; R John Solaro
Journal:  Circulation       Date:  2017-01-19       Impact factor: 29.690

Review 5.  GPCR biased ligands as novel heart failure therapeutics.

Authors:  Jonathan D Violin; David G Soergel; Guido Boerrigter; John C Burnett; Michael W Lark
Journal:  Trends Cardiovasc Med       Date:  2013-03-15       Impact factor: 6.677

Review 6.  Acute adenosinergic cardioprotection in ischemic-reperfused hearts.

Authors:  John P Headrick; Ben Hack; Kevin J Ashton
Journal:  Am J Physiol Heart Circ Physiol       Date:  2003-11       Impact factor: 4.733

Review 7.  Adrenergic nervous system in heart failure: pathophysiology and therapy.

Authors:  Anastasios Lymperopoulos; Giuseppe Rengo; Walter J Koch
Journal:  Circ Res       Date:  2013-08-30       Impact factor: 17.367

8.  Overexpression of the serotonin 5-HT2B receptor in heart leads to abnormal mitochondrial function and cardiac hypertrophy.

Authors:  Canan G Nebigil; Fabrice Jaffré; Nadia Messaddeq; Pierre Hickel; Laurent Monassier; Jean-Marie Launay; Luc Maroteaux
Journal:  Circulation       Date:  2003-06-16       Impact factor: 29.690

9.  Pharmacology of the Adenosine A3 Receptor in the Vasculature and Essential Hypertension.

Authors:  Ming-Fen Ho; Leanne M Low; Roselyn B Rose'Meyer
Journal:  PLoS One       Date:  2016-02-23       Impact factor: 3.240

10.  Augmented sphingosine 1 phosphate receptor-1 signaling in cardiac fibroblasts induces cardiac hypertrophy and fibrosis through angiotensin II and interleukin-6.

Authors:  Sei-Ichiro Ohkura; Soichiro Usui; Shin-Ichiro Takashima; Noriko Takuwa; Kazuaki Yoshioka; Yasuo Okamoto; Yutaka Inagaki; Naotoshi Sugimoto; Teppei Kitano; Masayuki Takamura; Takashi Wada; Shuichi Kaneko; Yoh Takuwa
Journal:  PLoS One       Date:  2017-08-03       Impact factor: 3.240

View more
  56 in total

Review 1.  Reverse Cardiac Remodeling and ARNI Therapy.

Authors:  Andrew Abboud; James L Januzzi
Journal:  Curr Heart Fail Rep       Date:  2021-01-22

2.  Coupling to Gq Signaling Is Required for Cardioprotection by an Alpha-1A-Adrenergic Receptor Agonist.

Authors:  Bat-Erdene Myagmar; Taylor Ismaili; Philip M Swigart; Anaha Raghunathan; Anthony J Baker; Sunil Sahdeo; Jonathan M Blevitt; Marcos E Milla; Paul C Simpson
Journal:  Circ Res       Date:  2019-08-20       Impact factor: 17.367

Review 3.  Leveraging Signaling Pathways to Treat Heart Failure With Reduced Ejection Fraction.

Authors:  Miguel Pinilla-Vera; Virginia S Hahn; David A Kass
Journal:  Circ Res       Date:  2019-05-24       Impact factor: 17.367

4.  Differential Activation of P-TEFb Complexes in the Development of Cardiomyocyte Hypertrophy following Activation of Distinct G Protein-Coupled Receptors.

Authors:  Ryan D Martin; Yalin Sun; Sarah MacKinnon; Luca Cuccia; Viviane Pagé; Terence E Hébert; Jason C Tanny
Journal:  Mol Cell Biol       Date:  2020-06-29       Impact factor: 4.272

5.  The European Research Network on Signal Transduction (ERNEST): Toward a Multidimensional Holistic Understanding of G Protein-Coupled Receptor Signaling.

Authors:  Martha E Sommer; Jana Selent; Jens Carlsson; Chris De Graaf; David E Gloriam; Gyorgy M Keseru; Mickey Kosloff; Stefan Mordalski; Aurelien Rizk; Mette M Rosenkilde; Eddy Sotelo; Johanna K S Tiemann; Andrew Tobin; Nina Vardjan; Maria Waldhoer; Peter Kolb
Journal:  ACS Pharmacol Transl Sci       Date:  2020-03-31

Review 6.  Gut Microbiota and Cardiovascular Disease.

Authors:  Marco Witkowski; Taylor L Weeks; Stanley L Hazen
Journal:  Circ Res       Date:  2020-07-30       Impact factor: 17.367

Review 7.  Calcium Signaling in Cardiomyocyte Function.

Authors:  Guillaume Gilbert; Kateryna Demydenko; Eef Dries; Rosa Doñate Puertas; Xin Jin; Karin Sipido; H Llewelyn Roderick
Journal:  Cold Spring Harb Perspect Biol       Date:  2020-03-02       Impact factor: 10.005

8.  Ellagic Acid Prevents Ca2+ Dysregulation and Improves Functional Abnormalities of Ventricular Myocytes via Attenuation of Oxidative Stress in Pathological Cardiac Hypertrophy.

Authors:  Bilge E Yamasan; Tanju Mercan; Orhan Erkan; Semir Ozdemir
Journal:  Cardiovasc Toxicol       Date:  2021-04-28       Impact factor: 3.231

9.  β1-adrenergic receptor N-terminal cleavage by ADAM17; the mechanism for redox-dependent downregulation of cardiomyocyte β1-adrenergic receptors.

Authors:  Jing Zhu; Susan F Steinberg
Journal:  J Mol Cell Cardiol       Date:  2021-02-06       Impact factor: 5.000

Review 10.  Physiological and pathological roles of protein kinase A in the heart.

Authors:  Yuening Liu; Jingrui Chen; Shayne K Fontes; Erika N Bautista; Zhaokang Cheng
Journal:  Cardiovasc Res       Date:  2022-01-29       Impact factor: 10.787

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.